

ACCESS DB # 256781  
PLEASE PRINT CLEARLY

FOR OFFICIAL USE ONLY

4-1-3 105

Scientific and Technical Information Center

## SEARCH REQUEST FORM

Requester's Full Name: Kristin Bianchi Examiner #:          Date: 4/8/08  
 Art Unit: 4131 Phone Number: 65232 Serial Number: 10/524977  
 Location (Bldg/Room#): OD16 (Mailbox #): N/A Results Format Preferred (circle): PAPER DISK  
 \*\*\*\*\*

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following: MEY

Title of Invention: Derivatives of 3-hydroxy-4-  
(Cycloalkylaminoalkyl)-5-phenyl-1H-  
pyrazole as antagonists of the  
Thomas Bird, Michael Maudet  
 Earliest Priority Date: 08/21/2002 Gonadotropin releasing hormone (GHRH)

## Search Topic:

08/21/2002  
 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.



\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

please search claims 11, 13 & 17. If the  
 elected compound (ie claim 11) isn't found,  
 please broaden the search.

=&gt; d ibib abs ind hitstr l6 1-1

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:182700 HCAPLUS Full-text  
 DOCUMENT NUMBER: 140:235705  
 TITLE: Preparation of pyrazole derivatives as antagonists of  
 gonadotropin releasing hormone (gnrh) for treating sex  
 hormone related conditions  
 INVENTOR(S): Bird, Thomas Geoffrey Colerick;  
 Herdemann, Matthias Ferdinand; Maudet,  
 Mickael Louis Pierre  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited  
 SOURCE: PCT Int. Appl., 156 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004017961	A2	20040304	WO 2003-GB3633	20030819
WO 2004017961	A3	20040408		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003255820	A1	20040311	AU 2003-255820	20030819
EP 1531811	A2	20050525	EP 2003-792487	20030819
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006505528	T	20060216	JP 2004-530361	20030819
US 20060287379	A1	20061221	US 2005-524977	20051128
PRIORITY APPLN. INFO.:			EP 2002-292077	A 20020821
			WO 2003-GB3633	W 20030819
OTHER SOURCE(S):	MARPAT 140:235705			
GI				



- AB Title compds. I [R1 = H, (un)substituted-alkyl, aryl, or arylalkyl; R2 = (un)substituted mono or bicyclic aromatic ring; R3 = arylalkylaminoalkyl, heterocyclalkylaminoalkyl, etc.; M = -(CH<sub>2</sub>)<sub>0-20</sub>-, or -CONH-; R5 = H, halo, heterocyclalkylcarbonylalkyl, etc.] and their pharmaceutically acceptable salts are prepared and disclosed as gonadotropin releasing hormone antagonists. Thus, e.g., II, was prepared in a multistep synthesis from Me 3,5-dimethylbenzoate and butyrolactone. In test assays, I possessed activity at concns. from 1 nM to 5  $\mu$ M.
- IC ICM A61K031-4155
- CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 2, 63
- ST pyrazole prepn gonadotropin releasing hormone antagonist
- IT Drug delivery systems  
Human  
Sexual disorders  
(preparation of pyrazoles as antagonists of gonadotropin releasing hormone)
- IT Gonadotropin-releasing hormone receptor  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of pyrazoles as antagonists of gonadotropin releasing hormone)
- IT Gonadotropin antagonists  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrazoles as antagonists of gonadotropin releasing hormone)
- IT 667459-73-6P 667459-74-7P 667459-75-8P  
667459-76-9P 667459-77-0P 667459-78-1P  
667459-79-2P 667459-80-5P 667459-81-6P  
667459-82-7P 667459-83-8P 667459-84-9P  
667459-85-0P 667459-86-1P 667459-87-2P  
667459-88-3P 667459-89-4P 667459-90-7P  
667459-91-8P 667459-92-9P 667459-93-0P  
667459-94-1P 667459-95-2P 667459-96-3P  
667459-97-4P 667459-98-5P 667459-99-6P  
667460-00-6P 667460-01-7P 667460-02-8P  
667460-03-9P 667460-04-0P 667460-05-1P  
667460-06-2P 667460-07-3P 667460-08-4P  
667460-09-5P 667460-10-8P 667460-11-9P  
667460-12-0P 667460-13-1P 667460-14-2P

667460-15-3P 667460-16-4P 667460-17-5P  
 667460-18-6P 667460-19-7P 667460-20-0P  
 667460-21-1P 667460-22-2P 667460-23-3P  
 667460-24-4P 667460-25-5P 667460-26-6P  
 667460-27-7P 667460-28-8P 667460-29-9P  
 667460-30-2P 667460-31-3P 667460-32-4P  
 667460-33-5P 667460-34-6P 667460-35-7P  
 667460-36-8P 667460-37-9P 667460-38-0P  
 667460-39-1P 667460-40-4P 667460-41-5P  
 667460-42-6P 667460-43-7P 667460-44-8P  
 667460-45-9P 667460-46-0P 667460-47-1P  
 667460-48-2P 667460-49-3P 667460-50-6P  
 667460-51-7P 667460-52-8P 667460-53-9P  
 667460-54-0P 667460-55-1P 667460-56-2P  
 667460-57-3P 667460-58-4P 667460-59-5P  
 667460-60-8P 667460-61-9P 667460-62-0P  
 667460-63-1P 667460-64-2P 667460-65-3P  
 667460-66-4P 667460-67-5P 667460-68-6P  
 667460-69-7P 667460-70-0P 667460-71-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(drug candidate; preparation of pyrazoles as antagonists of gonadotropin  
 releasing hormone)

IT 99778-39-9P 376364-27-1P 667460-72-2P  
 667460-73-3P 667460-74-4P 667460-75-5P  
 667460-76-6P 667460-77-7P 667460-78-8P  
 667460-79-9P 667460-80-2P 667460-81-3P  
 667460-82-4P 667460-83-5P 667460-84-6P  
 667460-85-7P 667460-86-8P 667460-87-9P  
 667460-88-0P 667460-89-1P 667460-90-4P  
 667460-91-5P 667460-92-6P 667460-94-8P  
 667460-95-9P 667460-96-0P 667460-97-1P  
 667460-98-2P 667460-99-3P 667461-00-9P  
 667461-01-0P 667461-02-1P 667461-03-2P  
 667461-04-3P 667461-05-4P 667461-06-5P  
 667461-07-6P 667461-08-7P 667461-09-8P  
 667461-10-1P 667461-11-2P 667461-12-3P  
 667461-13-4P 667461-14-5P 667461-15-6P  
 667461-16-7P 667461-17-8P 667461-18-9P  
 667461-19-0P 667461-20-3P 667461-21-4P  
 667461-22-5P 667461-23-6P 667461-24-7P  
 667461-25-8P 667461-26-9P 667461-27-0P  
 667461-28-1P 667461-29-2P 667461-30-5P  
 667461-31-6P 667461-32-7P 667461-33-8P  
 667461-34-9P 667461-35-0P 667461-36-1P  
 667461-37-2P 667461-38-3P 667461-39-4P  
 667461-40-7P 667461-41-8P 667461-42-9P  
 667461-43-0P 667461-44-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(intermediate; preparation of pyrazoles as antagonists of gonadotropin  
 releasing hormone)

IT 60-12-8, 2-Phenylethanol 93-53-8, 2-Phenylpropanal  
 96-09-3, Phenylloxirane 96-48-0, Butyrolactone  
 103-69-5, N-Ethylaniline 104-10-9, 2-(4-  
 Aminophenyl)ethanol 105-13-5, 4-Methoxybenzyl alcohol  
 581-45-3 589-08-2, N-Methyl-N-(2-phenylethyl)amine  
 622-08-2, 2-(Benzyloxy)ethanol 699-02-5,  
 2-(4-Methylphenyl)ethanol 702-23-8, 2-(4-Methoxyphenyl)ethanol

771-99-3, 4-Phenylpiperidine 936-44-7 1485-07-0  
 , 2-(Naphthalen-2-yl)ethanol 1875-88-3, 2-(4-Chlorophenyl)ethanol 1875-89-4, 2-(3-Methylphenyl)ethanol 2038-57-5, Benzenepropanamine 2629-72-3, 3-(Pyridin-4-yl)propanol 2759-28-6, N-Benzylpiperazine 2843-17-6, 3-Bromo-2,2-dimethylpropanoic acid 2859-67-8, 3-(Pyridin-3-yl)propanol 2932-58-3, 2-(2-Fluorophenyl)ethanol 3273-14-1, 1H-1,2,4-Triazole-1-ethanol 3325-11-9, 5-Aminobenzotriazole 3360-41-6, 4-Phenylbutanol 4265-99-0 4266-02-8 4407-36-7, trans-3-Phenylprop-2-enol 4441-30-9, 3-(Morpholin-4-yl)propanol 4442-79-9, 2-(Cyclohexyl)ethanol 5020-41-7, 2-(3-Methoxyphenyl)ethanol 5182-44-5, 2-(3-Chlorophenyl)ethanol 5264-15-3, 4-(4-Hydroxybutyl)pyridine 5321-49-3, N-(2-Phenylethyl)piperazine 5344-27-4, 4-(2-Hydroxyethyl)pyridine 5402-55-1, 2-(Thiophen-2-yl)ethanol 5406-86-0, 2-(4-tert-Butylphenyl)ethanol 5638-76-6 6006-82-2, 1,3-Benzodioxole-5-ethanol 6972-51-6, 2-(2,5-Dimethylphenyl)ethanol 7417-20-1, 2-(3,5-Dimethoxyphenyl)ethanol 7417-21-2, 2-(3,4-Dimethoxyphenyl)ethanol 7589-27-7, 2-(4-Fluorophenyl)ethanol 13214-66-9, Benzenebutanamine 15433-79-1 17734-21-3, Benzenepentanamine 23580-89-4 25081-39-4, Methyl 3,5-dimethylbenzoate 30595-79-0, 2-(2,6-Dichlorophenyl)ethanol 32231-06-4 33867-36-6, 5-Oxaspiro[2.4]heptan-6-one 35364-79-5, 2-(3,4-Dichlorophenyl)ethanol 37785-48-1, 2-(3,4,5-Trimethoxyphenyl)ethanol 39890-45-4, 1-(Pyrrolidinocarbonylmethyl)piperazine 39890-46-5 50438-75-0 52059-53-7, 2-(3-Fluorophenyl)ethanol 52244-70-9, 4-(4-Methoxyphenyl)butanol 55455-92-0, N-(3-Phenylpropyl)piperazine 62089-74-1, N-(Pyridin-4-ylmethyl)piperazine 62174-83-8, 4-(4-Aminobutyl)pyridine 64190-48-3 69395-13-7, 2-(4-Cyanophenyl)ethanol 79524-20-2, 4-(4-Nitrophenyl)butanol 94022-96-5, 2-(2-Trifluoromethylphenyl)ethanol 97480-93-8, N-(4-Phenylbutyl)piperazine 118943-21-8, 3-(4-Methoxyphenoxy)propanol 121356-79-4, 2-Pyrimidinebutanol 145943-75-5 205194-33-8 214262-86-9, 2-(2-Chloro-6-fluorophenyl)ethanol 246219-84-1 246231-23-2 263393-50-6 286440-92-4, 2-(3,4-Difluorophenyl)ethanol 318280-95-4 467223-90-1 667461-46-3, Pyrazinebutanol 667461-51-0, 2-(4-Chloro-2-fluorophenyl)ethanol 667461-54-3 667461-56-5 667461-58-7 667461-59-8 667461-60-1 667461-61-2 667461-62-3 667461-63-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrazoles as antagonists of gonadotropin releasing hormone)

IT 667459-73-6P 667459-74-7P 667459-75-8P  
 667459-76-9P 667459-77-0P 667459-78-1P  
 667459-79-2P 667459-80-5P 667459-81-6P  
 667459-82-7P 667459-83-8P 667459-84-9P  
 667459-85-0P 667459-86-1P 667459-87-2P  
 667459-88-3P 667459-89-4P 667459-90-7P  
 667459-91-8P 667459-92-9P 667459-93-0P  
 667459-94-1P 667459-95-2P 667459-96-3P  
 667459-97-4P 667459-98-5P 667459-99-6P  
 667460-00-6P 667460-01-7P 667460-02-8P

667460-03-9P 667460-04-0P 667460-05-1P  
 667460-06-2P 667460-07-3P 667460-08-4P  
 667460-09-5P 667460-10-8P 667460-11-9P  
 667460-12-0P 667460-13-1P 667460-14-2P  
 667460-15-3P 667460-16-4P 667460-17-5P  
 667460-18-6P 667460-19-7P 667460-20-0P  
 667460-21-1P 667460-22-2P 667460-23-3P  
 667460-24-4P 667460-25-5P 667460-26-6P  
 667460-27-7P 667460-28-8P 667460-29-9P  
 667460-30-2P 667460-31-3P 667460-32-4P  
 667460-33-5P 667460-34-6P 667460-35-7P  
 667460-36-8P 667460-37-9P 667460-38-0P  
 667460-39-1P 667460-40-4P 667460-41-5P  
 667460-42-6P 667460-43-7P 667460-44-8P  
 667460-45-9P 667460-46-0P 667460-47-1P  
 667460-48-2P 667460-49-3P 667460-50-6P  
 667460-51-7P 667460-52-8P 667460-53-9P  
 667460-54-0P 667460-55-1P 667460-56-2P  
 667460-57-3P 667460-58-4P 667460-59-5P  
 667460-60-8P 667460-61-9P 667460-62-0P  
 667460-63-1P 667460-64-2P 667460-65-3P  
 667460-66-4P 667460-67-5P 667460-68-6P  
 667460-69-7P 667460-70-0P 667460-71-1P



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(drug candidate; preparation of pyrazoles as antagonists of gonadotropin  
 releasing hormone)

RN 667459-73-6 HCAPLUS




CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[2-(4-  
 pyridinyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-  
 oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 667459-74-7 HCAPLUS  
 CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[3-(4-pyridinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667459-75-8 HCAPLUS  
 CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[3-(3-pyridinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 667459-76-9 HCAPLUS  
 CN Pyrrolidine, 1-[3-[[4-[2-[[2-(4-cyanophenyl)ethyl]amino]ethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A










RN 667459-77-0 HCAPLUS

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[2-(4-methoxyphenyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)





RN 667459-78-1 HCAPLUS


10/524,977

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[3-(4-methoxyphenoxy)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 667459-79-2 HCAPLUS

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 667459-80-5 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667459-81-6 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[2-(4-pyridinyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667459-82-7 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[2-(1H-1,2,4-triazol-1-yl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667459-83-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[2-[[3-(4-acetyl-1-piperazinyl)propyl]amino]ethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667459-84-9 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[3-(4-morpholinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667459-85-0 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[3-(1,1-dioxido-4-thiomorpholinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667459-86-1 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667459-87-2 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(4-pyridinyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/524,977

RN 667459-88-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[4-(4-pyridinyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-89-4 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[3-(4-pyridinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-90-7 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[4-phenylbutyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667459-91-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[4-(4-

10/524,977

methoxyphenyl)butyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-92-9 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[4-(4-nitrophenyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-93-0 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[4-(2-pyrimidinyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667459-94-1 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[4-(pyrazinyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-



10/524,977

oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-95-2 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(4-cyanophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-96-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(2-naphthalenyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-97-4 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(phenylmethoxy)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-98-5 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[(2-phenylethyl)amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-99-6 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-[3-(trifluoromethyl)phenyl]ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-00-6 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-01-7 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-[4-(dimethylamino)phenyl]ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-02-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(4-fluorophenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-03-9 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(3,5-difluorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/524,977



RN 667460-04-0 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-[4-(1,1-dimethylethyl)phenyl]ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-05-1 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(2,5-dimethylphenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-06-2 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/524,977



RN 667460-07-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(4-chloro-2-fluorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-08-4 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(3,4-dichlorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-09-5 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(2,6-dichlorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/524,977



RN 667460-10-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-oxo-2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-11-9 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-[(3aS,6aR)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-12-0 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(3-fluorophenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/524,977



RN 667460-13-1 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(3-chlorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-14-2 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(3-methoxyphenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-15-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(3-methylphenyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/524,977



RN 667460-16-4 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(4-chlorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-17-5 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(4-methylphenyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-18-6 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(4-methoxyphenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/524,977



RN 667460-19-7 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(2-fluorophenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-20-0 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(3,4-difluorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-21-1 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(3,5-dimethoxyphenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/524,977



RN 667460-22-2 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(3,4,5-trimethoxyphenyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-23-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[3-(4-methoxyphenoxy)propyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-24-4 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-25-5 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(phenylamino)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-26-6 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[(3-phenyl-2-propenyl)amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 667460-27-7 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[4-methoxyphenyl)methyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-28-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-[4-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-29-9 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(4-aminophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-30-2 HCAPLUS

CN Cyclopentanecarboxamide, N-[4-[2-[[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]ethyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/524,977



RN 667460-31-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-[4-[bis(methylsulfonyl)amino]phenyl]ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-32-4 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(2-thienyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-33-5 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-[4-[(methylsulfonyl)amino]phenyl]ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/524,977



RN 667460-34-6 HCAPLUS

CN Carbamic acid, [4-[2-[[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]ethyl]phenyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-35-7 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-[4-[[[(cyclohexylamino)carbonyl]amino]phenyl]ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-36-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[(2-cyclohexylethyl)amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/524,977



RN 667460-37-9 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(1,2-dihydro-1-methyl-2-oxo-6-quinoliny)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-38-0 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[(2-hydroxy-2-phenylethyl)amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-39-1 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[(2-phenylpropyl)amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-40-4 HCAPLUS

CN Acetamide, 2-[[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]-N-1H-benzotriazol-5-yl]- (9CI) (CA INDEX NAME)



RN 667460-41-5 HCAPLUS

CN Pyrrolidine, 1-[[[4-[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)






10/524,977


RN 667460-42-6 HCAPLUS

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[3-(4-pyridinyl)-1-pyrrolidinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI)  
(CA INDEX NAME)



RN 667460-43-7 HCAPLUS


CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-44-8 HCAPLUS

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI)  
(CA INDEX NAME)



10/524,977




RN 667460-45-9 HCAPLUS

CN Morpholine, 4-[[4-[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-1-piperazinyl]acetyl]- (9CI)  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 667460-46-0 HCAPLUS

CN 1-Piperazineacetamide, 4-[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-N-methyl-N-phenyl- (CA INDEX NAME)






RN 667460-47-1 HCAPLUS

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(2-phenylethyl)-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-48-2 HCAPLUS

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(4-pyridinylmethyl)-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-49-3 HCAPLUS  
 CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(3-phenylpropyl)-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI)  
 (CA INDEX NAME)



10/524,977


RN 667460-50-6 HCAPLUS

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(4-phenylbutyl)-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI)  
(CA INDEX NAME)





RN 667460-51-7 HCAPLUS

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperidinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)






PAGE 1-A






RN 667460-52-8 HCAPLUS  
 CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[3-[4-(trifluoromethyl)phenyl]-1-piperidinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-53-9 HCAPLUS  
 CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[methyl(2-phenylethyl)amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-54-0 HCAPLUS

CN 2-Azabicyclo[2.2.2]octane, 2-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(3-methoxyphenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-55-1 HCAPLUS


CN 2-Azabicyclo[2.2.2]octane, 2-[3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-56-2 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[1-[[[2-(3-methoxyphenyl)ethyl]amino]methyl]cyclopropyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-57-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(4-phenyl-1-piperidyl)methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI)  
(CA INDEX NAME)



RN 667460-58-4 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[[4-(4-phenylbutyl)-1-piperazinyl]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-59-5 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[[methyl(3-phenylpropyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




10/524,977




RN 667460-60-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 667460-61-9 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]methyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-62-0 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[[4-(4-pyridinyl)-1-piperidinyl]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-63-1 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[[4-(tetrahydro-2H-pyran-4-yl)-1-piperidinyl]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-64-2 HCAPLUS


10/524,977

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[[methyl(4-phenylbutyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]-(9CI) (CA INDEX NAME)




RN 667460-65-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[[4-phenylbutyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]-(9CI) (CA INDEX NAME)




RN 667460-66-4 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[[methyl(5-phenylpentyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]-(9CI) (CA INDEX NAME)




RN 667460-67-5 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[[3-phenylpropyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]-(9CI) (CA INDEX NAME)




RN 667460-68-6 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[[5-phenylpentyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-69-7 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(3-phenyl-1-pyrrolidinyl)methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-70-0 HCAPLUS

CN 1-Propanol, 3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-71-1 HCAPLUS

CN Propanoic acid, 3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 99778-39-9P 376364-27-1P 667460-72-2P  
 667460-73-3P 667460-74-4P 667460-75-5P  
 667460-76-6P 667460-77-7P 667460-78-8P  
 667460-79-9P 667460-80-2P 667460-81-3P  
 667460-82-4P 667460-83-5P 667460-84-6P  
 667460-85-7P 667460-86-8P 667460-87-9P  
 667460-88-0P 667460-89-1P 667460-90-4P  
 667460-91-5P 667460-92-6P 667460-94-8P  
 667460-95-9P 667460-96-0P 667460-97-1P  
 667460-98-2P 667460-99-3P 667461-00-9P  
 667461-01-0P 667461-02-1P 667461-03-2P  
 667461-04-3P 667461-05-4P 667461-06-5P  
 667461-07-6P 667461-08-7P 667461-09-8P  
 667461-10-1P 667461-11-2P 667461-12-3P  
 667461-13-4P 667461-14-5P 667461-15-6P  
 667461-16-7P 667461-17-8P 667461-18-9P  
 667461-19-0P 667461-20-3P 667461-21-4P  
 667461-22-5P 667461-23-6P 667461-24-7P  
 667461-25-8P 667461-26-9P 667461-27-0P  
 667461-28-1P 667461-29-2P 667461-30-5P  
 667461-31-6P 667461-32-7P 667461-33-8P  
 667461-34-9P 667461-35-0P 667461-36-1P  
 667461-37-2P 667461-38-3P 667461-39-4P  
 667461-40-7P 667461-41-8P 667461-42-9P  
 667461-43-0P 667461-44-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazoles as antagonists of gonadotropin releasing hormone)

CN	Acetamide, N-1H-benzotriazol-5-yl-2-chloro-	(9CI)	(CA INDEX NAME)
----	---	-------	-----------------



Absolute stereochemistry.

CC1=C(C)C(C(=O)C2CCC(=O)O2)=CC=C1C


RN 667460-73-3 HCAPLUS

CC1=CC=C(C=C1C2=CNC(=O)C2)CCO

46


10/524,977

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-(2-hydroxyethyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-75-5 HCAPLUS

CN Pyrrolidine, 1-[3-[[4-(2-aminoethyl)-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)






RN 667460-76-6 HCAPLUS

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[2,4-dinitrophenyl)sulfonyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-77-7 HCAPLUS

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[2,4-dinitrophenyl)sulfonyl][2-(4-pyridinyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-78-8 HCAPLUS




CN Pyrrolidine, 1-(3-bromo-2,2-dimethyl-1-oxopropyl)- (9CI) (CA INDEX NAME)





RN 667460-79-9 HCAPLUS


CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[2,4-dinitrophenyl)sulfonyl][3-(4-pyridinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)








RN 667460-80-2 HCAPLUS  
 CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[ (2,4-dinitrophenyl)sulfonyl][3-(3-pyridinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)







RN 667460-81-3 HCAPLUS  
 CN Pyrrolidine, 1-[3-[[4-[2-[[2-(4-cyanophenyl)ethyl][(2,4-dinitrophenyl)sulfonyl]amino]ethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-82-4 HCAPLUS  
 CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[2-(4-methoxyphenyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A



RN 667460-83-5 HCAPLUS  
 CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[ (2,4-dinitrophenyl)sulfonyl][3-(4-methoxyphenoxy)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 667460-84-6 HCAPLUS

CN Benzenepropanoic acid, 3,5-dimethyl- $\beta$ -oxo-, methyl ester (CA INDEX NAME)




RN 667460-85-7 HCAPLUS

CN Benzenepropanoic acid, 3,5-dimethyl- $\beta$ -oxo- $\alpha$ -2-propenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 667460-86-8 HCAPLUS

CN 3H-Pyrazol-3-one, 5-(3,5-dimethylphenyl)-1,2-dihydro-4-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 667460-87-9 HCAPLUS

CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-(2-propenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-88-0 HCAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






RN 667460-89-1 HCAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-(2-oxoethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 667460-90-4 HCAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 667460-91-5 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-(2-hydroxyethyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-92-6 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-(2-aminoethyl)-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

10/524,977




RN 667460-94-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[[(2,4-dinitrophenyl)sulfonyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-95-9 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[[(2,4-dinitrophenyl)sulfonyl][4-(4-pyridinyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-96-0 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-(3-bromo-2,2-dimethyl-1-oxopropyl)- (9CI)

(CA INDEX NAME)




RN 667460-97-1 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[[(2,4-dinitrophenyl)sulfonyl][2-(4-pyridinyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667460-98-2 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[[(2,4-dinitrophenyl)sulfonyl][2-(1H-1,2,4-triazol-1-yl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-99-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[2-[[3-(4-acetyl-1-oxo-1H-pyrazol-5-yl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




10/524,977

piperazinyl)propyl] [(2,4-dinitrophenyl)sulfonyl]amino]ethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667461-00-9 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[[(2,4-dinitrophenyl)sulfonyl][3-(4-morpholinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667461-01-0 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[[(2,4-dinitrophenyl)sulfonyl][3-(1,1-dioxido-4-thiomorpholinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667461-02-1 HCAPLUS

CN 3H-Pyrazol-3-one, 5-(3,5-dimethylphenyl)-1,2-dihydro-4-[(1S)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-03-2 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-04-3 HCAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-4-[(1S)-2-hydroxy-1-methylethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-05-4 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-amino-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-06-5 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-07-6 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl][(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


10/524,977



RN 667461-08-7 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[ (2,4-dinitrophenyl)sulfonyl][2-(4-pyridinyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-09-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[ (2,4-dinitrophenyl)sulfonyl][4-(4-pyridinyl)butyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-10-1 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[ (2,4-dinitrophenyl)sulfonyl][3-(4-pyridinyl)propyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-11-2 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[ (2,4-dinitrophenyl)sulfonyl][4-phenylbutyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-12-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[ (2,4-dinitrophenyl)sulfonyl][4-(4-methoxyphenyl)butyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-13-4 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[[(2,4-dinitrophenyl)sulfonyl][4-(4-nitrophenyl)butyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-14-5 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[[(2,4-dinitrophenyl)sulfonyl][4-(2-pyrimidinyl)butyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-15-6 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(4-dinitrophenyl)sulfonyl](4-pyrazinylbutyl)amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-16-7 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(4-cyanophenyl)ethyl][(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-17-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(4-dinitrophenyl)sulfonyl][2-(2-naphthalenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-18-9 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2,4-dinitrophenyl)sulfonyl][2-(phenylmethoxy)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667461-19-0 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2,4-dinitrophenyl)sulfonyl](2-phenylethyl)amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/524,977



RN 667461-20-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[ (2,4-dinitrophenyl)sulfonyl][2-(4-fluorophenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667461-21-4 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(3,5-difluorophenyl)ethyl][(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/524,977




RN 667461-22-5 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[ (2,4-dinitrophenyl)sulfonyl][2-[4-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 667461-23-6 HCAPLUS

10/524,977

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(4-aminophenyl)ethyl][(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.





RN 667461-24-7 HCAPLUS

CN Carbamic acid, [4-[2-[[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl][(2,4-dinitrophenyl)sulfonyl]amino]ethyl]phenyl]-, 1-methylethyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 667461-25-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(1,2-dihydro-1-methyl-2-oxo-7-quinoliny]ethyl][(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]-(9CI) (CA INDEX NAME)




RN 667461-26-9 HCAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-[2-[4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 667461-27-0 HCAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-[2-[3-(4-pyridinyl)-1-pyrrolidinyl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 667461-28-1 HCAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 667461-29-2 HCAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-4-(2-hydroxyethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 667461-30-5 HCAPLUS


CN 1H-Pyrazole-1-carboxylic acid, 3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-4-(2-bromoethyl)-5-(3,5-dimethylphenyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 667461-31-6 HCAPLUS

CN 2-Azabicyclo[2.2.2]octane, 2-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-32-7 HCAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[3-(2-azabicyclo[2.2.2]oct-2-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-4-[(1S)-2-hydroxy-1-methylethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 667461-33-8 HCAPLUS

CN 2-Azabicyclo[2.2.2]octane, 2-[3-[[4-[(1S)-2-amino-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA

10/524,977

INDEX NAME)


Absolute stereochemistry.



RN 667461-34-9 HCAPLUS


CN 2-Azabicyclo[2.2.2]octane, 2-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[[(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667461-35-0 HCAPLUS

CN 2-Azabicyclo[2.2.2]octane, 2-(3-bromo-2,2-dimethyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 667461-36-1 HCAPLUS

CN 5-Oxaspiro[2.4]heptan-6-one, 7-(3,5-dimethylbenzoyl)- (CA INDEX NAME)




RN 667461-37-2 HCAPLUS

CN 3H-Pyrazol-3-one, 5-(3,5-dimethylphenyl)-1,2-dihydro-4-[1-(hydroxymethyl)cyclopropyl]- (CA INDEX NAME)




RN 667461-38-3 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[1-(hydroxymethyl)cyclopropyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667461-39-4 HCAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-4-[1-(hydroxymethyl)cyclopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)






10/524,977


RN 667461-40-7 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[1-(aminomethyl)cyclopropyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667461-41-8 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[1-[[[(2,4-dinitrophenyl)sulfonyl]amino]methyl]cyclopropyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667461-42-9 HCAPLUS

CN 3H-Pyrazol-3-one, 5-(3,5-dimethylphenyl)-1,2-dihydro- (CA INDEX NAME)



RN 667461-43-0 HCAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667461-44-1 HCAPLUS

CN Propanoic acid, 3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-  
(CA INDEX NAME)

Absolute stereochemistry.



IT 60-12-8, 2-Phenylethanol 93-53-8, 2-Phenylpropanal  
96-09-3, Phenylloxirane 96-48-0, Butyrolactone  
103-69-5, N-Ethylaniline 104-10-9, 2-(4-  
Aminophenyl)ethanol 105-13-5, 4-Methoxybenzyl alcohol  
581-45-3 589-08-2, N-Methyl-N-(2-phenylethyl)amine  
622-08-2, 2-(Benzyloxy)ethanol 699-02-5,  
2-(4-Methylphenyl)ethanol 702-23-8, 2-(4-Methoxyphenyl)ethanol  
771-99-3, 4-Phenylpiperidine 936-44-7 1485-07-0  
, 2-(Naphthalen-2-yl)ethanol 1875-88-3, 2-(4-  
Chlorophenyl)ethanol 1875-89-4, 2-(3-Methylphenyl)ethanol  
2038-57-5, Benzenepropanamine 2629-72-3,  
3-(Pyridin-4-yl)propanol 2759-28-6, N-Benzylpiperazine  
2843-17-6, 3-Bromo-2,2-dimethylpropanoic acid 2859-67-8,  
3-(Pyridin-3-yl)propanol 2932-58-3, 2-(2-Fluorophenyl)ethanol  
3273-14-1, 1H-1,2,4-Triazole-1-ethanol 3325-11-9,  
5-Aminobenzotriazole 3360-41-6, 4-Phenylbutanol  
4265-99-0 4266-02-8 4407-36-7,  
trans-3-Phenylprop-2-enol 4441-30-9, 3-(Morpholin-4-yl)propanol  
4442-79-9, 2-(Cyclohexyl)ethanol 5020-41-7,  
2-(3-Methoxyphenyl)ethanol 5182-44-5, 2-(3-Chlorophenyl)ethanol  
5264-15-3, 4-(4-Hydroxybutyl)pyridine 5321-49-3,  
N-(2-Phenylethyl)piperazine 5344-27-4, 4-(2-  
Hydroxyethyl)pyridine 5402-55-1, 2-(Thiophen-2-yl)ethanol  
5406-86-0, 2-(4-tert-Butylphenyl)ethanol 5638-76-6  
6006-82-2, 1,3-Benzodioxole-5-ethanol 6972-51-6,  
2-(2,5-Dimethylphenyl)ethanol 7417-20-1, 2-(3,5-  
Dimethoxyphenyl)ethanol 7417-21-2, 2-(3,4-  
Dimethoxyphenyl)ethanol 7589-27-7, 2-(4-Fluorophenyl)ethanol  
13214-66-9, Benzenebutanamine 15433-79-1  
17734-21-3, Benzenepentanamine 23580-89-4

10/524,977

25081-39-4, Methyl 3,5-dimethylbenzoate 30595-79-0,  
2-(2,6-Dichlorophenyl)ethanol 32231-06-4 33867-36-6,  
5-Oxaspiro[2.4]heptan-6-one 35364-79-5, 2-(3,4-  
Dichlorophenyl)ethanol 37785-48-1, 2-(3,4,5-  
Trimethoxyphenyl)ethanol 39890-45-4, 1-  
(Pyrrolidinocarbonylmethyl)piperazine 39890-46-5  
50438-75-0 52059-53-7, 2-(3-Fluorophenyl)ethanol  
52244-70-9, 4-(4-Methoxyphenyl)butanol 55455-92-0,  
N-(3-Phenylpropyl)piperazine 62089-74-1, N-(Pyridin-4-  
ylmethyl)piperazine 62174-83-8, 4-(4-Aminobutyl)pyridine  
64190-48-3 69395-13-7, 2-(4-Cyanophenyl)ethanol  
79524-20-2, 4-(4-Nitrophenyl)butanol 94022-96-5,  
2-(2-Trifluoromethylphenyl)ethanol 97480-93-8,  
N-(4-Phenylbutyl)piperazine 118943-21-8, 3-(4-  
Methoxyphenoxy)propanol 121356-79-4, 2-Pyrimidinebutanol  
145943-75-5 205194-33-8 214262-86-9,  
2-(2-Chloro-6-fluorophenyl)ethanol 246219-84-1  
246231-23-2 263393-50-6 286440-92-4,  
2-(3,4-Difluorophenyl)ethanol 318280-95-4 467223-90-1  
667461-46-3, Pyrazinebutanol 667461-51-0,  
2-(4-Chloro-2-fluorophenyl)ethanol 667461-54-3  
667461-56-5 667461-58-7 667461-59-8  
667461-60-1 667461-61-2 667461-62-3  
667461-63-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrazoles as antagonists of gonadotropin  
releasing hormone)


RN 60-12-8 HCAPLUS

CN Benzeneethanol (CA INDEX NAME)




RN 93-53-8 HCAPLUS

CN Benzeneacetaldehyde,  $\alpha$ -methyl- (CA INDEX NAME)



RN 96-09-3 HCAPLUS


CN Oxirane, 2-phenyl- (CA INDEX NAME)




RN 96-48-0 HCAPLUS

CN 2(3H)-Furanone, dihydro- (CA INDEX NAME)


10/524,977




RN 103-69-5 HCAPLUS  
CN Benzenamine, N-ethyl- (CA INDEX NAME)




RN 104-10-9 HCAPLUS  
CN Benzenethanol, 4-amino- (CA INDEX NAME)




RN 105-13-5 HCAPLUS  
CN Benzenemethanol, 4-methoxy- (CA INDEX NAME)



RN 581-45-3 HCAPLUS  
CN Pyridine, 4-(4-piperidinyl)- (CA INDEX NAME)




RN 589-08-2 HCAPLUS  
CN Benzenethanamine, N-methyl- (CA INDEX NAME)




RN 622-08-2 HCAPLUS  
CN Ethanol, 2-(phenylmethoxy)- (CA INDEX NAME)


10/524,977




RN 699-02-5 HCAPLUS  
CN Benzeneethanol, 4-methyl- (CA INDEX NAME)




RN 702-23-8 HCAPLUS  
CN Benzeneethanol, 4-methoxy- (CA INDEX NAME)




RN 771-99-3 HCAPLUS  
CN Piperidine, 4-phenyl- (CA INDEX NAME)



RN 936-44-7 HCAPLUS  
CN Pyrrolidine, 3-phenyl- (CA INDEX NAME)




RN 1485-07-0 HCAPLUS  
CN 2-Naphthaleneethanol (CA INDEX NAME)



RN 1875-88-3 HCAPLUS


10/524,977

CN Benzeneethanol, 4-chloro- (CA INDEX NAME)



RN 1875-89-4 HCAPLUS

CN Benzeneethanol, 3-methyl- (CA INDEX NAME)




RN 2038-57-5 HCAPLUS

CN Benzenepropanamine (CA INDEX NAME)




RN 2629-72-3 HCAPLUS

CN 4-Pyridinepropanol (CA INDEX NAME)



RN 2759-28-6 HCAPLUS


CN Piperazine, 1-(phenylmethyl)- (CA INDEX NAME)




RN 2843-17-6 HCAPLUS

CN Propanoic acid, 3-bromo-2,2-dimethyl- (CA INDEX NAME)


10/524,977




RN 2859-67-8 HCAPLUS  
CN 3-Pyridinepropanol (CA INDEX NAME)




RN 2932-58-3 HCAPLUS  
CN Benzeneethanol, β-fluoro- (CA INDEX NAME)




RN 3273-14-1 HCAPLUS  
CN 1H-1,2,4-Triazole-1-ethanol (CA INDEX NAME)



RN 3325-11-9 HCAPLUS  
CN 1H-Benzotriazol-6-amine (CA INDEX NAME)



RN 3360-41-6 HCAPLUS  
CN Benzenebutanol (CA INDEX NAME)



RN 4265-99-0 HCAPLUS  
CN Benzenebutanamine, N-methyl- (CA INDEX NAME)

10/524,977




RN 4266-02-8 HCAPLUS  
CN Benzenepentanamine, N-methyl- (CA INDEX NAME)




RN 4407-36-7 HCAPLUS  
CN 2-Propen-1-ol, 3-phenyl-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.




RN 4441-30-9 HCAPLUS  
CN 4-Morpholinepropanol (CA INDEX NAME)



RN 4442-79-9 HCAPLUS  
CN Cyclohexaneethanol (CA INDEX NAME)




RN 5020-41-7 HCAPLUS  
CN Benzeneethanol, 3-methoxy- (CA INDEX NAME)




RN 5182-44-5 HCAPLUS  
CN Benzeneethanol, 3-chloro- (CA INDEX NAME)







RN 5264-15-3 HCAPLUS  
 CN 4-Pyridinebutanol (CA INDEX NAME)




RN 5321-49-3 HCAPLUS  
 CN Piperazine, 1-(2-phenylethyl)- (CA INDEX NAME)




RN 5344-27-4 HCAPLUS  
 CN 4-Pyridineethanol (CA INDEX NAME)



RN 5402-55-1 HCAPLUS  
 CN 2-Thiopheneethanol (CA INDEX NAME)




RN 5406-86-0 HCAPLUS  
 CN Benzeneethanol, 4-(1,1-dimethylethyl)- (CA INDEX NAME)




10/524,977


RN 5638-76-6 HCAPLUS  
CN 2-Pyridineethanamine, N-methyl- (CA INDEX NAME)




RN 6006-82-2 HCAPLUS  
CN 1,3-Benzodioxole-5-ethanol (CA INDEX NAME)




RN 6972-51-6 HCAPLUS  
CN Benzeneethanol, 2,5-dimethyl- (CA INDEX NAME)



RN 7417-20-1 HCAPLUS  
CN Benzeneethanol, 3,5-dimethoxy- (CA INDEX NAME)




RN 7417-21-2 HCAPLUS  
CN Benzeneethanol, 3,4-dimethoxy- (CA INDEX NAME)



RN 7589-27-7 HCAPLUS  
CN Benzeneethanol, 4-fluoro- (CA INDEX NAME)


10/524,977



RN 13214-66-9 HCAPLUS  
CN Benzenebutanamine (CA INDEX NAME)



RN 15433-79-1 HCAPLUS  
CN 2-Furanmethanol, 5-[(dimethylamino)methyl]- (CA INDEX NAME)




RN 17734-21-3 HCAPLUS  
CN Benzenepentanamine (CA INDEX NAME)



RN 23580-89-4 HCAPLUS  
CN Benzenepropanamine, N-methyl- (CA INDEX NAME)




RN 25081-39-4 HCAPLUS  
CN Benzoic acid, 3,5-dimethyl-, methyl ester (CA INDEX NAME)




RN 30595-79-0 HCAPLUS  
CN Benzeneethanol, 2,6-dichloro- (CA INDEX NAME)

10/524,977




RN 32231-06-4 HCAPLUS

CN Piperazine, 1-(1,3-benzodioxol-5-ylmethyl)- (CA INDEX NAME)




RN 33867-36-6 HCAPLUS

CN 5-Oxaspiro[2.4]heptan-6-one (CA INDEX NAME)




RN 35364-79-5 HCAPLUS

CN Benzeneethanol, 3,4-dichloro- (CA INDEX NAME)



RN 37785-48-1 HCAPLUS


CN Benzeneethanol, 3,4,5-trimethoxy- (CA INDEX NAME)




RN 39890-45-4 HCAPLUS

CN Ethanone, 2-(1-piperazinyl)-1-(1-pyrrolidinyl)- (CA INDEX NAME)


10/524,977




RN 39890-46-5 HCAPLUS  
CN Ethanone, 1-(4-morpholinyl)-2-(1-piperazinyl)- (CA INDEX NAME)




RN 50438-75-0 HCAPLUS  
CN Benzeneethanol, 4-(dimethylamino)- (CA INDEX NAME)



RN 52059-53-7 HCAPLUS  
CN Benzeneethanol, 3-fluoro- (CA INDEX NAME)




RN 52244-70-9 HCAPLUS  
CN Benzenebutanol, 4-methoxy- (CA INDEX NAME)




RN 55455-92-0 HCAPLUS  
CN Piperazine, 1-(3-phenylpropyl)- (CA INDEX NAME)


10/524,977



RN 62089-74-1 HCAPLUS  
CN Piperazine, 1-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 62174-83-8 HCAPLUS  
CN 4-Pyridinebutanamine (CA INDEX NAME)




RN 64190-48-3 HCAPLUS  
CN 2(3H)-Furanone, dihydro-4-methyl-, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 69395-13-7 HCAPLUS  
CN Benzonitrile, 4-(2-hydroxyethyl)- (CA INDEX NAME)




RN 79524-20-2 HCAPLUS  
CN Benzenebutanol, 4-nitro- (CA INDEX NAME)

10/524,977




RN 94022-96-5 HCAPLUS

CN Benzeneethanol, 2-(trifluoromethyl)- (CA INDEX NAME)




RN 97480-93-8 HCAPLUS

CN Piperazine, 1-(4-phenylbutyl)- (CA INDEX NAME)




RN 118943-21-8 HCAPLUS

CN 1-Propanol, 3-(4-methoxyphenoxy)- (CA INDEX NAME)



RN 121356-79-4 HCAPLUS


CN 2-Pyrimidinebutanol (CA INDEX NAME)



RN 145943-75-5 HCAPLUS


CN 1-Piperazinepropanol, 4-acetyl- (9CI) (CA INDEX NAME)

10/524,977




RN 205194-33-8 HCAPLUS

CN 4-Thiomorpholinepropanol, 1,1-dioxide (CA INDEX NAME)




RN 214262-86-9 HCAPLUS

CN Benzeneethanol, 2-chloro-6-fluoro- (CA INDEX NAME)




RN 246219-84-1 HCAPLUS

CN Methanesulfonamide, N-[4-(2-hydroxyethyl)phenyl]- (CA INDEX NAME)



RN 246231-23-2 HCAPLUS


CN Methanesulfonamide, N-[4-(2-hydroxyethyl)phenyl]-N-(methanesulfonyl)- (CA INDEX NAME)






10/524,977


RN 263393-50-6 HCAPLUS  
CN Piperidine, 4-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 286440-92-4 HCAPLUS  
CN Benzeneethanol, 3,4-difluoro- (CA INDEX NAME)




RN 318280-95-4 HCAPLUS  
CN 1-Piperazineacetamide, N-methyl-N-phenyl- (CA INDEX NAME)




RN 467223-90-1 HCAPLUS  
CN Benzeneethanol, 3,5-difluoro- (CA INDEX NAME)



RN 667461-46-3 HCAPLUS  
CN Pyrazinebutanol (9CI) (CA INDEX NAME)




RN 667461-51-0 HCAPLUS  
CN Benzeneethanol, 4-chloro-2-fluoro- (CA INDEX NAME)



RN 667461-54-3 HCAPLUS

CN 4H-1,3-Dioxolo[4,5-c]pyrrole, tetrahydro-5-(hydroxyacetyl)-, (3aR,6aS)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-56-5 HCAPLUS


CN 5H-1,3-Dioxolo[4,5-c]pyrrole-5-ethanol, tetrahydro-, (3aR,6aS)- (CA INDEX  
NAME)

Absolute stereochemistry.




RN 667461-58-7 HCAPLUS

CN Urea, N-[4-(2-hydroxyethyl)phenyl]-N'-(1-methylethyl)- (CA INDEX NAME)



RN 667461-59-8 HCAPLUS


CN Cyclopentanecarboxamide, N-[4-(2-hydroxyethyl)phenyl]- (CA INDEX NAME)



RN 667461-60-1 HCAPLUS


10/524,977

CN Carbamic acid, [4-(2-hydroxyethyl)phenyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 667461-61-2 HCAPLUS

CN Urea, N-cyclohexyl-N'-[4-(2-hydroxyethyl)phenyl]- (CA INDEX NAME)




RN 667461-62-3 HCAPLUS

CN 2(1H)-Quinolinone, 6-(2-hydroxyethyl)-1-methyl- (CA INDEX NAME)



RN 667461-63-4 HCAPLUS

CN Piperidine, 3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



## NOTE ABOUT NOMENCLATURE OF REQUESTED COMPOUND

I was unsure of how to interpret the nomenclature for the requested compound, 2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-(2S)-propylamine.

The compound could be the same as RN 667459-86-1, named by CAS as 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]-.

It could be the same as RN 667459-86-1, except for the pyrazol numbering, "pyrazol-4-yl" by the applicant, and "pyrazol-3-yl" by CAS.

I sent the two compound names to Chemical Abstracts Service for comparison by their nomenclature experts, and received the following response:

Dear Mary Jane,

Thank you for your inquiry. Editorial was willing to help with the nomenclature question. They cannot guarantee that this name represents RN 667459-86-1 because the position of the nitrogen in the azabicyclo[2.2.1] heptane ring in the CN sent is not specified. RN

667459-86-1 represents the substance containing the ring 7-azabicyclo[2.2.1]heptane. The position of the N in this ring could be 1,2, or 7. This is the only ambiguity in this name. Everything else corresponds to the structure represented by RN 667459-86-1.

Best regards,

Dan

CAS Customer Care  
Phone: (+1) 800-848-6533  
Fax: (+1) 614-447-3798


I have proceeded with the search as if the requested compound is the same as 667459-86-1. Perhaps the applicant can clarify the name provided in the claims.

Mary Jane Ruhl  
Remsen 1-A-61  
Extension 22524  
Maryjane.ruhl@uspto.gov

## RESULTS FROM REGISTRY AND CAPLUS

(The compound was searched by Registry Number and as a structure, yielding two compounds but one citation. A search in Beilstein yielded zero hits.)

=> d que stat l22  
L19 STR



NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 42



STEREO ATTRIBUTES: NONE  
L21 2 SEA FILE=REGISTRY SSS FUL L19  
L22 1 SEA FILE=HCAPLUS ABB=ON L21

=> d ibib abs hitstr l22 1

L22 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:182700 HCAPLUS [Full-text](#)  
DOCUMENT NUMBER: 140:235705  
TITLE: Preparation of pyrazole derivatives as antagonists of gonadotropin releasing hormone (gnrh) for treating sex hormone related conditions  
INVENTOR(S): Bird, Thomas Geoffrey Colerick; Herdemann, Matthias Ferdinand; Maudet, Mickael Louis Pierre  
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited  
SOURCE: PCT Int. Appl., 156 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004017961	A2	20040304	WO 2003-GB3633	20030819
WO 2004017961	A3	20040408		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003255820	A1	20040311	AU 2003-255820	20030819
EP 1531811	A2	20050525	EP 2003-792487	20030819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505528	T	20060216	JP 2004-530361	20030819
US 20060287379	A1	20061221	US 2005-524977	20051128
PRIORITY APPLN. INFO.:			EP 2002-292077	A 20020821
			WO 2003-GB3633	W 20030819
OTHER SOURCE(S):		MARPAT 140:235705		
GI				



AB Title compds. I [R1 = H, (un)substituted-alkyl, aryl, or arylalkyl; R2 = (un)substituted mono or bicyclic aromatic ring; R3 = arylalkylaminoalkyl, heterocyclylalkylaminoalkyl, etc.; M = -(CH<sub>2</sub>)<sub>0-20</sub>-, or -CONH-; R5 = H, halo, heterocyclylcarbonylalkyl, etc.] and their pharmaceutically acceptable salts are prepared and disclosed as gonadotropin releasing hormone antagonists. Thus, e.g., II, was prepared in a multistep synthesis from Me 3,5-

10/524,977

dimethylbenzoate and butyrolactone. In test assays, I possessed activity at concns. from 1 nM to 5  $\mu$ M.


IT 667459-86-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazoles as antagonists of gonadotropin releasing hormone)

RN 667459-86-1 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




IT 667461-07-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazoles as antagonists of gonadotropin releasing hormone)

RN 667461-07-6 HCAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



## SEARCH HISTORY

=&gt; d his ful

(FILE 'HOME' ENTERED AT 14:14:55 ON 16 APR 2008)

FILE 'REGISTRY' ENTERED AT 14:15:57 ON 16 APR 2008

FILE 'REGISTRY' ENTERED AT 14:16:22 ON 16 APR 2008

L1 1 SEA ABB=ON 667459-86-1/RN

FILE 'HCAPLUS' ENTERED AT 14:16:36 ON 16 APR 2008

L2 1 SEA ABB=ON L1

FILE 'REGISTRY' ENTERED AT 14:17:20 ON 16 APR 2008

E AZABICYCLO[2.2.1]HEPTANE/CN

FILE 'HCAPLUS' ENTERED AT 14:18:56 ON 16 APR 2008

L3 776 SEA ABB=ON ?AZABICYCLO?(W)2.2.1(W)?HEPTANE?

L4 9 SEA ABB=ON L3 AND ?BENZODIOXOL?(W)5(W)YL

L5 15 SEA ABB=ON L3 AND ?BENZODIOXOL?

L6 71 SEA ABB=ON L3 AND ?PYRAZOL?

L7 74 SEA ABB=ON L4 OR L5 OR L6

L8 62 SEA ABB=ON L7 AND ?DIMETHYL?

L9 9 SEA ABB=ON L8 AND ?OXOPROPYL?

D AU 1-9

L10 29 SEA ABB=ON L8 AND ?METHYLETHYL?

D AU 1-29

L11 917 SEA ABB=ON ?AZABICYCLO?(W)2.2.1(W)?HEPTAN?

L12 51 SEA ABB=ON L11 AND 2,2(W)?DIMETHYL?

L13 32 SEA ABB=ON L12 AND ?OXO?

L14 16 SEA ABB=ON L13 AND ?PROPOXY?

L15 17 SEA ABB=ON L11 AND ?BENZODIOXOL?

L16 80 SEA ABB=ON L11 AND ?PYRAZOL?

L17 46 SEA ABB=ON L16 AND OXO?

L18 22 SEA ABB=ON L16 AND ?PROPOXY?

FILE 'REGISTRY' ENTERED AT 14:52:35 ON 16 APR 2008

L19 STRUCTURE 667459-86-1

L20 0 SEA SSS SAM L19

L21 2 SEA SSS FUL L19

FILE 'HCAPLUS' ENTERED AT 14:53:22 ON 16 APR 2008

L22 1 SEA ABB=ON L21

FILE 'BEILSTEIN' ENTERED AT 14:55:41 ON 16 APR 2008

L23 0 SEA ABB=ON L21

L24 0 SEA ABB=ON L21

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2008 HIGHEST RN 1015083-77-8

DICTIONARY FILE UPDATES: 15 APR 2008 HIGHEST RN 1015083-77-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

#### FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Apr 2008 VOL 148 ISS 16  
FILE LAST UPDATED: 15 Apr 2008 (20080415/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

#### FILE BEILSTEIN

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.

FILE CONTAINS 10,322,808 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

```
*****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.          *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE    *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                  *
* FOR PRICE INFORMATION SEE HELP COST                           *
*****
```

10/524,977

>>> Price change as of January 1st, 2008: Connect Time and Structure  
Search fees re-introduced. See NEWS and HELP COST <<<